Osterix-Cre marks distinct subsets of CD45- and CD45+ stromal populations in extra-skeletal tumors with pro-tumorigenic characteristics

  1. Biancamaria Ricci
  2. Eric Tycksen
  3. Hamza Celik
  4. Jad I Belle
  5. Francesca Fontana
  6. Roberto Civitelli
  7. Roberta Faccio  Is a corresponding author
  1. Washington University in St Louis, United States

Abstract

Cancer-associated fibroblasts (CAFs) are a heterogeneous population of mesenchymal cells supporting tumor progression, whose origin remains to be fully elucidated. Osterix (Osx) is a marker of osteogenic differentiation, expressed in skeletal progenitor stem cells and bone-forming osteoblasts. We report Osx expression in CAFs and by using Osx-cre;TdTomato reporter mice we confirm the presence and pro-tumorigenic function of TdTOSX+ cells in extra-skeletal tumors. Surprisingly, only a minority of TdTOSX+ cells expresses fibroblast and osteogenic markers. The majority of TdTOSX+ cells express the hematopoietic marker CD45, have a genetic and phenotypic profile resembling that of tumor infiltrating myeloid and lymphoid populations, but with higher expression of lymphocytic immune suppressive genes. We find Osx transcript and Osx protein expression early during hematopoiesis, in subsets of hematopoietic stem cells and multipotent progenitor populations. Our results indicate that Osx marks distinct tumor promoting CD45- and CD45+ populations and challenge the dogma that Osx is expressed exclusively in cells of mesenchymal origin.

Data availability

Sequencing data are deposited in GEO under accession code GSE143586https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE143586

The following data sets were generated

Article and author information

Author details

  1. Biancamaria Ricci

    Orthopedics, Washington University in St Louis, St Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1574-6043
  2. Eric Tycksen

    Genetics, Washington University in St Louis, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Hamza Celik

    Internal Medicine, Washington University in St Louis, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Jad I Belle

    Medicine, Washington University in St Louis, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Francesca Fontana

    Internal Medicine, Washington University in St Louis, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Roberto Civitelli

    Internal Medicine, Washington University in St Louis, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4076-4315
  7. Roberta Faccio

    Orthopedics, Washington University in St Louis, St. Louis, United States
    For correspondence
    faccior@wustl.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1639-2005

Funding

National Institutes of Health (R01 CA235096)

  • Roberta Faccio

National Institutes of Health (R01 AR066551)

  • Roberta Faccio

Shriners Hospital (P19-07408CR)

  • Roberta Faccio

Siteman Cancer Center

  • Roberto Civitelli
  • Roberta Faccio

JIT Award by Washinghton University Institute for Clinical and Translational Sciences (TR000448)

  • Francesca Fontana
  • Roberto Civitelli

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All the animals were handled according to the Institutional Animal Care and Use Committee (IACUC) protocols (#2016-0228 and # 2019-0982 to RF, #2014-0279 and #2017-0095 to RC).

Reviewing Editor

  1. Ivo Kalajzic, UConn Health, United States

Publication history

  1. Received: December 21, 2019
  2. Accepted: July 27, 2020
  3. Accepted Manuscript published: August 5, 2020 (version 1)
  4. Version of Record published: August 14, 2020 (version 2)

Copyright

© 2020, Ricci et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,679
    Page views
  • 194
    Downloads
  • 7
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Biancamaria Ricci
  2. Eric Tycksen
  3. Hamza Celik
  4. Jad I Belle
  5. Francesca Fontana
  6. Roberto Civitelli
  7. Roberta Faccio
(2020)
Osterix-Cre marks distinct subsets of CD45- and CD45+ stromal populations in extra-skeletal tumors with pro-tumorigenic characteristics
eLife 9:e54659.
https://doi.org/10.7554/eLife.54659

Further reading

    1. Cancer Biology
    2. Computational and Systems Biology
    Matthew Roberts, Julia Ogden ... Carlos Lopez-Garcia
    Tools and Resources Updated

    Lung squamous cell carcinoma (LUSC) is a type of lung cancer with a dismal prognosis that lacks adequate therapies and actionable targets. This disease is characterized by a sequence of low- and high-grade preinvasive stages with increasing probability of malignant progression. Increasing our knowledge about the biology of these premalignant lesions (PMLs) is necessary to design new methods of early detection and prevention, and to identify the molecular processes that are key for malignant progression. To facilitate this research, we have designed XTABLE (Exploring Transcriptomes of Bronchial Lesions), an open-source application that integrates the most extensive transcriptomic databases of PMLs published so far. With this tool, users can stratify samples using multiple parameters and interrogate PML biology in multiple manners, such as two- and multiple-group comparisons, interrogation of genes of interests, and transcriptional signatures. Using XTABLE, we have carried out a comparative study of the potential role of chromosomal instability scores as biomarkers of PML progression and mapped the onset of the most relevant LUSC pathways to the sequence of LUSC developmental stages. XTABLE will critically facilitate new research for the identification of early detection biomarkers and acquire a better understanding of the LUSC precancerous stages.

    1. Biochemistry and Chemical Biology
    2. Cancer Biology
    Mark Borris D Aldonza, Junghwa Cha ... Yoosik Kim
    Research Article

    Cancer secretome is a reservoir for aberrant glycosylation. How therapies alter this post- translational cancer hallmark and the consequences thereof remain elusive. Here we show that an elevated secretome fucosylation is a pan-cancer signature of both response and resistance to multiple targeted therapies. Large-scale pharmacogenomics revealed that fucosylation genes display widespread association with resistance to these therapies. In cancer cell cultures, xenograft mouse models, and patients, targeted kinase inhibitors distinctively induced core fucosylation of secreted proteins less than 60 kDa. Label-free proteomics of N-glycoproteomes identified fucosylation of the antioxidant PON1 as a critical component of the therapy-induced secretome (TIS). N-glycosylation of TIS and target core fucosylation of PON1 are mediated by the fucose salvage-FUT8-SLC35C1 axis with PON3 directly modulating GDP-Fuc transfer on PON1 scaffolds. Core fucosylation in the Golgi impacts PON1 stability and folding prior to secretion, promoting a more degradation-resistant PON1. Global and PON1-specific secretome de-N-glycosylation both limited the expansion of resistant clones in a tumor regression model. We defined the resistance-associated transcription factors (TFs) and genes modulated by the N-glycosylated TIS via a focused and transcriptome-wide analyses. These genes characterize the oxidative stress, inflammatory niche, and unfolded protein response as important factors for this modulation. Our findings demonstrate that core fucosylation is a common modification indirectly induced by targeted therapies that paradoxically promotes resistance.